These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9647171)

  • 1. Systemic T cell adoptive immunotherapy of malignant gliomas.
    Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S
    J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
    Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.
    To WC; Wood BG; Krauss JC; Strome M; Esclamado RM; Lavertu P; Dasko D; Kim JA; Plautz GE; Leff BE; Smith V; Sandstrom-Wakeling K; Shu S
    Arch Otolaryngol Head Neck Surg; 2000 Oct; 126(10):1225-31. PubMed ID: 11031409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell adoptive immunotherapy of metastatic renal cell carcinoma.
    Plautz GE; Bukowski RM; Novick AC; Klein EA; Kursh ED; Olencki TE; Yetman RJ; Pienkny A; Sandstrom K; Shu S
    Urology; 1999 Oct; 54(4):617-23; discussion 623-4. PubMed ID: 10510917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study.
    Harsh GR; Deisboeck TS; Louis DN; Hilton J; Colvin M; Silver JS; Qureshi NH; Kracher J; Finkelstein D; Chiocca EA; Hochberg FH
    J Neurosurg; 2000 May; 92(5):804-11. PubMed ID: 10794295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
    Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
    J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Curry WT; Gorrepati R; Piesche M; Sasada T; Agarwalla P; Jones PS; Gerstner ER; Golby AJ; Batchelor TT; Wen PY; Mihm MC; Dranoff G
    Clin Cancer Res; 2016 Jun; 22(12):2885-96. PubMed ID: 26873960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE; Touhalisky JE; Shu S
    Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous natural killer cell therapy for human recurrent malignant glioma.
    Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
    Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
    Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
    Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas.
    Tsuboi K; Saijo K; Ishikawa E; Tsurushima H; Takano S; Morishita Y; Ohno T
    Clin Cancer Res; 2003 Aug; 9(9):3294-302. PubMed ID: 12960115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.
    Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA
    J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.